10-K: SELLAS Life Sciences Group Reports on Executive Changes and Clinical Trial Progress

SELLAS Life Sciences Group announces executive departures, provides updates on clinical trials for GPS and SLS009, and discloses financial details.

Summary

• SELLAS Life Sciences Group has provided updates on its clinical programs and executive team.
• Robert Francomano, Senior Vice President and Chief Commercial Officer, and Barbara Wood, Executive Vice President, General Counsel and Corporate Secretary, have departed the company.
• The company's Phase 3 REGAL study for GPS in AML has completed enrollment, with interim analysis expected in the first half of 2024 and final analysis by the end of 2024.
• Positive topline data from the Phase 2a clinical trial of SLS009 in combination with aza/ven in r/r AML was announced, showing a 50% response rate in the 30 mg twice a week cohort.
• A Phase 1b/2 trial of SLS009 in r/r PTCL, funded by GenFleet, has begun in China, with initial data expected in the second quarter of 2024.
• A Phase 1b/2 trial of SLS009 in combination with Brukinsa in r/r DLBCL, funded by GenFleet, has also begun in China.
• The company's cash and cash equivalents balance as of December 31, 2023 was $2.5 million, which is not sufficient to fund operations for the next 12 months.
• The company has raised approximately $29 million in gross proceeds through a registered direct offering in March 2024 and a public offering in January 2024.
• The company has commenced a binding arbitration proceeding against 3D Medicines to resolve a dispute regarding milestone payments and development efforts for GPS in Greater China.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive clinical trial results and recent capital raises, the company's financial position is precarious, and there are ongoing disputes with a key partner. The executive departures also add uncertainty.

Positives

• The Phase 3 REGAL study for GPS in AML has completed enrollment, which is a significant milestone.
• The Phase 2a clinical trial of SLS009 in combination with aza/ven in r/r AML showed promising response rates, particularly in the 30 mg twice a week cohort.
• The initiation of Phase 1b/2 trials for SLS009 in PTCL and DLBCL, funded by GenFleet, expands the potential applications of the drug.
• The company has successfully raised additional capital through recent offerings, which will help fund ongoing operations.
• The company has identified potential biomarkers for SLS009 that may predict response to treatment.

Negatives

• The company's cash and cash equivalents balance as of December 31, 2023 was $2.5 million, which is not sufficient to fund operations for the next 12 months.
• The company has commenced a binding arbitration proceeding against 3D Medicines, indicating a dispute over milestone payments and development efforts for GPS in Greater China.
• The company has announced the departure of two key executives, which may cause disruption.
• The company has incurred significant losses since inception and anticipates continuing to incur losses for the foreseeable future.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The outcome of the arbitration proceeding with 3D Medicines is uncertain and could impact future revenue.
• Clinical trials may not produce favorable results or receive regulatory approval.
• The company faces substantial competition in the oncology therapeutic market.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or disruptions.
• The company's product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval.
• The company may not be able to obtain and enforce patent rights or other intellectual property rights that cover its product candidates.
• The company's commercial success depends on market acceptance of its product candidates, if approved, among physicians, patients, health care payors and cancer treatment centers.
• The company may be adversely affected by changes in applicable laws or regulations.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues to research, develop and seek regulatory approvals for its product candidates and any additional product candidates it may acquire, and potentially begin to commercialize product candidates that may achieve regulatory approval. The company anticipates that its research and development expenses will increase for the foreseeable future as it conducts and completes its ongoing early and late-stage clinical trials, initiates additional clinical trials, and expands regulatory activities associated with the preparation and submission of regulatory filings.

Management Comments

• Management believes that the planned interim analysis after 60 events per the protocol will occur in the first half of 2024 and that the final analysis after 80 events will occur by the end of 2024.
• Management continues to evaluate different strategies to obtain the required funding for future operations.

Industry Context

The oncology therapeutic market is highly competitive, with numerous companies developing novel treatments. SELLAS is focused on developing better treatments for AML, the lead indication for both GPS and SLS009, which will allow it to leverage its clinical development expertise in hematology/oncology and to build a single streamlined commercial infrastructure sufficient for both of its current product candidates.

Comparison to Industry Standards

• The median OS of 21.0 months in patients receiving GPS therapy compared to 5.4 months in the AML CR2 patients treated with best standard care in the Moffitt trial is a significant improvement over historical data.
• The median OS of 18.4 months in the GPS and pembrolizumab combination trial compared to 13.8 months with pembrolizumab alone in a similar patient population is a positive result.
• The median OS of 70.3 weeks (17.6 months) in patients who received the combination therapy of GPS and nivolumab in the MPM trial is a positive result compared to historical data.
• The 1.87-fold increase in median PFS with GPS in MM compared to a historical cohort is a positive result.
• The 100% response rate at the optimal dose level (30 mg BIW) and 57% response rate across all dose levels in the Phase 2a trial of SLS009 in combination with aza/ven in r/r AML is a positive result.
• The 36.4% response rate in the subgroup of PTCL patients in the Phase 1 trial of SLS009 is a positive result.

Management Changes

Legal Proceedings

• The company has commenced a binding arbitration proceeding against 3D Medicines to resolve a dispute regarding milestone payments and development efforts for GPS in Greater China.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and uncertainty due to the company's financial position.
• Employees may experience uncertainty due to executive departures and potential restructuring.
• Patients may benefit from the continued development of promising cancer therapies.
• Partners and suppliers may be affected by the company's financial situation and ongoing legal disputes.

Next Steps

• The company will continue to advance the development of GPS and SLS009, including the Phase 3 REGAL clinical trial of GPS in AML and the ongoing and planned clinical trials of SLS009.
• The company will continue to evaluate different strategies to obtain the required funding for future operations.
• The company will continue to pursue discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to its product candidates.
• The company will continue to monitor the progress of the arbitration proceeding with 3D Medicines.

Key Dates

Keywords

SELLAS Life Sciences, Galinpepimut-S, GPS, SLS009, CDK9 inhibitor, AML, Acute Myeloid Leukemia, PTCL, Peripheral T-cell Lymphoma, DLBCL, Diffuse Large B-Cell Lymphoma, Clinical Trial, Immunotherapy, Oncology, Biopharmaceutical, 3D Medicines, GenFleet, FDA, Orphan Drug Designation, Fast Track Designation, Capital Raise